Top Nasdaq Stocks is issuing a report on four stocks to watch. Athersys, Inc. (NASDAQ:ATHX), Teekay Offshore Partners L.P. (NYSE:TOO), Caladrius Biosciences Inc (NASDAQ:CLBS), and Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) have been added to our watch list today. Continue reading to find out why. – To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
Stay Informed and Up To Date On The Hottest NASDAQ Plays like ATHX. Get Them Here
Teekay Offshore Partners L.P. (NYSE:TOO) reported earnings in late February. Results showed that Gross margins widened from 31.89% to 34.70% compared to the same period last year, operating (EBITDA) margins now 52.26% from 44.74%. Additionally, analysts are citing that the company’s earnings growth has been influenced by improvements in operating (EBIT) margins from 25.27% to 29.92% as well as one-time items. The company’s pretax margins are now 5.78% compared to 0.93% for the same period last year. Teekay’s combined entities manage and operate consolidated assets of over $13 billion, comprised of approximately 220 liquefied gas, offshore, and conventional tanker assets. With offices in 15 countries and approximately 7,100 seagoing and shore-based employees, Teekay provides a comprehensive set of marine services to the world’s leading oil and gas companies. Monday (3/14) the stock has seen an increase in price of more than 24% in early market activity.
Members of record by 4PM March 14 will secure a place holder to receive our next report. Get Your Free Membership Now.
Caladrius Biosciences Inc (NASDAQ:CLBS) announced this morning that the company, through its subsidiary, PCT, has entered into a global collaboration with Hitachi Chemical Co., Ltd. that includes licensing, development and equity components. Hitachi Chemical is a global conglomerate with a growing franchise in life sciences, including regenerative medicine. Through the agreement, Hitachi Chemical has purchased a 19.9% equity interest in PCT for $19.4 million. Caladrius will retain the remaining 80.1% ownership of PCT. CLBS has moved up in price by as much as 60% since Friday’s closing price (3/11). Caladrius is a leading cell therapy company combining an industry-leading development and manufacturing services provider with a select therapeutic product pipeline
Enjoy picks like this? Get These Alerts and More on NASDAQ Companies before They Rally, Text the word “NASDAQ” to 77948
Stay Informed and Up To Date On The Hottest NASDAQ Plays. Get Them Here
Looking for stock market and business news headlines? How about up to the minute information on mutual funds and ETFs? Don’t forget about the top stock picks of 2016. TopNasdaqStocks.com has it all. Make sure to subscribe to our free newsletter and to receive free text message alerts on your phone, text “NASDAQ” to 77948.
Disclosure: The information, opinions and analysis contained in this report are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not representative of future gains. Top Nasdaq Stocks has not been compensated nor does it expect to receive any compensation for distribution of its opinions and publicly available information regarding the companies reported in this investment opinion article at this time. The opinions contained herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. Top Nasdaq Stocks is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk. Please visit http://topnasdaqstocks.com/index.php/disclaimer/ website for a more detailed discussion of risks and disclosures.
Top Nasdaq Stocks
SOURCE: Top Nasdaq Stocks